A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 79-91

  Borges, Sahra ^a   Döppler, Heike R ^a   Storz, Peter ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast cancer; Invasive phenotype; MDA MB 231; Methyltransferase inhibitors; Suramin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE INHIBITOR; N PHTHALOYLTRYPTOPHAN; PROTEIN KINASE; PUROMYCIN; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CULTURE; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PHTHALIMIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURAMIN; TRYPTOPHAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896714346     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2857-2     Document Type: Article

References (60)

1. Karahoca M, Momparler RL (2013) Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenet 5:3
2. Singh V, Sharma P, Capalash N (2013) DNA methyltransferase inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 13:379-399
3. Karpf AR, Moore BC, Ririe TO, Jones DA (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 59:751-757
4. Eiseler T, Doppler H, Yan IK, Goodison S, Storz P (2009) Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 11:R13
5. Borges S, Doppler H, Perez EA, Andorfer CA, Sun Z et al (2013) Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res 15:R66
6. Chopin DK, Caruelle JP, Colombel M, Palcy S, Ravery V et al (1993) Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150:1126-1130
7. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z et al (1997) Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31:223-233
8. Ravery V, Jouanneau J, Gil Diez S, Abbou CC, Caruelle JP et al (1992) Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res 20:211-214
9. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M (2000) Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60:4245-4250
10. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR et al (1994) Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 145:365-374
11. Suzuki K, Tokue A, Kamiakito T, Kuriki K, Saito K et al (2001) Predominant expression of fibroblast growth factor (FGF) 8, FGF4, and FGF receptor 1 in nonseminomatous and highly proliferative components of testicular germ cell tumors. Virchows Arch 439:616-621
12. Bernsen HJ, Rijken PF, Peters JP, Bakker JH, Boerman RH et al (1999) Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 44:129-136
13. Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ et al (2007) Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg 11:171-178
14. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV et al (1993) Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68:932-938
15. Hawking F (1978) Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 15:289-322
16. Coffey RJ Jr, Goustin AS, Soderquist AM, Shipley GD, Wolfshohl J et al (1987) Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res 47:4590-4594
17. Hosang M (1985) Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29:265-273
18. Pollak M, Richard M (1990) Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349-1352
19. Williams LT, Tremble PM, Lavin MF, Sunday ME (1984) Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem 259:5287-5294
20. Hensey CE, Boscoboinik D, Azzi A (1989) Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 258:156-158
21. Buchinger B, Spitzer S, Karlic H, Klaushofer K, Varga F (2008) Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin. Cancer Lett 265:45-54
22. Wiese C, Nikolova T, Zahanich I, Sulzbacher S, Fuchs J et al (2011) Differentiation induction of mouse embryonic stem cells into sinus node-like cells by suramin. Int J Cardiol 147:95-111
23. Jiang S, Chen X, Li C, Zhang X, Zhang T et al (2012) Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin. Mol Med Rep 6:1351-1354
24. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239-2248
25. Bastea LI, Doppler H, Balogun B, Storz P (2012) Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound, inactive SNAI1 transcriptional repressor complex. PLoS ONE 7:e30459
26. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC (2010) Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res 70:7810-7819
27. Jaggi M, Rao PS, Smith DJ, Hemstreet GP, Balaji KC (2003) Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem Biophys Res Commun 307:254-260
28. Olayioye MA, Barisic S, Hausser A (2013) Multi-level control of actin dynamics by protein kinase D. Cell Signal 25:1739-1747
29. Storz P, Doppler H, Johannes FJ, Toker A (2003) Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation. J Biol Chem 278:17969-17976
30. Cowell CF, Doppler H, Yan IK, Hausser A, Umezawa Y et al (2009) Mitochondrial diacylglycerol initiates protein-kinase D1-mediated ROS signaling. J Cell Sci 122:919-928
31. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E et al (2012) An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10:56
32. Vignon F, Prebois C, Rochefort H (1992) Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84:38-42
33. Song S, Yu B, Wei Y, Wientjes MG, Au JL (2004) Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 10:6058-6065
34. Waldron RT, Rozengurt E (2003) Protein kinase C phosphorylates protein kinase D activation loop Ser744 and Ser748 and releases autoinhibition by the pleckstrin homology domain. J Biol Chem 278:154-163
35. Gschwendt M, Kittstein W, Johannes FJ (1998) Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities. FEBS Lett 421:165-168
36. Matthews SA, Rozengurt E, Cantrell D (1999) Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/Protein kinase Cmu. J Biol Chem 274:26543-26549
37. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A (2009) FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Mol Cell Biol 29:4906-4917
38. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ et al (1996) A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 39:1-8
39. Dreicer R, Smith DC, Williams RD, See WA (1999) Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 17:183-186
40. Falcone A, Pfanner E, Cianci C, Danesi R, Brunetti I et al (1995) Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. Cancer 75:440-443
41. George S, Dreicer R, Au JJ, Shen T, Rini BI et al (2008) Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 6:79-85
42. Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y et al (2012) Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol 70:49-56
43. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T et al (2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol 19:1903-1909
44. Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D et al (2003) Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin Cancer Res 9:3303-3311
45. Song S, Wientjes MG, Gan Y, Au JL (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A 97:8658-8663
46. Song S, Wientjes MG, Walsh C, Au JL (2001) Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 61:6145-6150
47. Zhang Y, Song S, Yang F, Au JL, Wientjes MG (2001) Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299:426-433
48. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S et al (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201:213-220
49. Zhu WG, Hileman T, Ke Y, Wang P, Lu S et al (2004) 5-Aza-2′- deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279:15161-15166
50. Constantinides PG, Jones PA, Gevers W (1977) Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267:364-366
51. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93
52. Eiseler T, Doppler H, Yan IK, Kitatani K, Mizuno K et al (2009) Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol 11:545-556
53. Eiseler T, Hausser A, De Kimpe L, Van Lint J, Pfizenmaier K (2010) Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. J Biol Chem 285:18672-18683
54. Eiseler T, Schmid MA, Topbas F, Pfizenmaier K, Hausser A (2007) PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration. FEBS Lett 581:4279-4287
55. Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA et al (2009) Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res 69:5634-5638
56. Spratley SJ, Bastea LI, Doppler H, Mizuno K, Storz P (2011) Protein kinase D regulates cofilin activity through p21-activated kinase 4. J Biol Chem 286:34254-34261
57. Kim M, Jang HR, Kim JH, Noh SM, Song KS et al (2008) Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis 29:629-637
58. Onishi Y, Kawamoto T, Kishimoto K, Hara H, Fukase N et al (2012) PKD1 negatively regulates cell invasion, migration and proliferation ability of human osteosarcoma. Int J Oncol 40:1839-1848
59. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM et al (2007) Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109:2579-2588
60. Sundram V, Chauhan SC, Ebeling M, Jaggi M (2012) Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS ONE 7:e35368